Neurosense Therapeutics is trading 5% down at $0.45 after its August 13, 2026 CEO letter highlighted delays securing funding for the Phase 3 PARAGON ALS study.
- Shareholders will vote on authorization for a potential 1-for-4 to 1-for-40 reverse split.
- The company continues Nasdaq compliance work, adding dilution and listing-risk concerns.
- The negative reaction appears company-specific despite broader markets trading higher.